Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Sirnaomics Says siRNA Effective in Phase II Basal Cell Carcinoma Trial

publication date: Feb 23, 2022

Sirnaomics (HK: 2257) reported positive interim data from a US Phase II trial of STP705, a siRNA (small interfering RNA) drug, for patients with cutaneous basal cell carcinoma. A total of 15 patients were enrolled, five in each of three cohorts of a dose escalation trial. In the two largest dose cohorts, three of the five patients experienced a complete response, while one in the lowest dose group also had a complete response. In general, patients showed an improved or stable cosmetic result with no significant cutaneous skin reactions. Sirnaomics is a Maryland-Suzhou siRNA company. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital